Your session is about to expire
What is Coumadin
Approved as Treatment by the FDA
Warfarin, otherwise known as Coumadin, is approved by the FDA for 11 uses which include Deep Vein Thrombosis (DVT) and prophylaxis of Thromboembolic event .Effectiveness
When to interrupt dosage
The measure of Coumadin is contingent upon the identified condition, including Pulmonary Embolism, Atrial Fibrillation and Heart Attack. The portion of dosage fluctuates as per the method of delivery specified in the table below.Warnings
Coumadin possesses twenty-seven contraindications, meaning it should not be administered when encountering any of the conditions given in the table below.Coumadin ContraindicationsCoumadin Novel Uses: Which Conditions Have a Clinical Trial Featuring Coumadin?
Currently, 301 active studies are assessing the potential of Coumadin to address Atrial Fibrillation, Disease and Pulmonary Embolism.Coumadin Reviews: What are patients saying about Coumadin?
Patient Q&A Section about coumadin
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.What are Coumadin side effects?
"You may have easy bruising and bleeding, nausea, vomiting, stomach pain, bloating, gas, or an altered sense of taste."
What is Coumadin used for?
"Warfarin is a prescription medication used to prevent harmful blood clots from forming or growing larger. Beneficial blood clots prevent or stop bleeding, but harmful blood clots can cause a stroke, heart attack, deep vein thrombosis, or pulmonary embolism."
What is the most common side effect of Coumadin?
"The blood thinner warfarin (sold under the brand name Coumadin) can cause a variety of side effects, including nausea, vomiting, diarrhea, and abdominal pain. The most common side effect, however, is bleeding, which can be fatal."
Why is Coumadin being taken off the market?
"Coumadin's manufacturer, Bristol-Myers Squibb, has announced the discontinuation of all strengths of the drug due to an unexpected manufacturing issue. The decision is not based on safety or efficacy concerns."